Research and Development Clinical Development Business Strategy, Marketing and Sales Legal Services
Click on a consultant's name to view their contact information
An accomplished pharmaceutical regulatory affairs professional, Ms. Kercher is highly experienced in the pharmaceutical/ biotechnology industry working with the CBER, CDER and OGD. Her areas of expertise include but are not limited to asthma, oncology, rheumatology, neurology, psychiatry and immunology.
Recently, Ms. Kercher created Strategic Biotechnology Consultants, a consulting service for drug development teams and management to ensure the optimal development plan is being pursued with the FDA. Her services outline, interpret and clarify FDA requirements, ensuring quality submissions to the FDA which result in reduced review times and accelerate time to market. Prior to starting her own company, Ms. Kercher worked for Immunex, Abbott Laboratories and Upjohn (Chugai-Upjohn).
Robin has more than 15 years of experience in public relations, public affairs, crisis management, marketing and advocacy work. She most recently served as Director of Communications at Immunex Corporation, where she was responsible for managing corporate and product public relations, media relations, issues management, public affairs, advocacy development and internal communications. She came to Immunex in 1994 as Manager of Corporate Communications and then moved to product management in 1997 to launch ENBREL® (etanercept), one of the fastest-selling biotechnology products launched in the bio/pharmaceutical industry. Prior to Immunex, Robin worked at Ogilvy & Mather Public Affairs in Washington, DC, where she managed a variety of health and environment-related accounts. Robin holds a Bachelor of Journalism degree in News-Editorial Writing (minor in Science Writing) and BA in Political Science from the University of Missouri-Columbia.
Annette established A.V. Bio Pharma Consulting to provide both strategic and applied Quality Assurance, Quality Control and Product Development services for companies with clinical and commercial products. Annette’s 20 years of experience span toxicology studies through product approval (FDA and EMEA) and commercialization. She came to Immunex in 1989, and during her 13 year tenure she held various management positions, with her most recent position as Vice President of Quality. Annette was instrumental in the development, approval and commercialization of ENBREL® (etanercept) in the United States and internationally. Prior to Immunex, Annette worked for Codon Corporation (now Berlex) and Enzyme Systems Products.